Skip to main content
Erschienen in: Reviews in Endocrine and Metabolic Disorders 3/2016

30.08.2016

Skin manifestations of growth hormone-induced diseases

verfasst von: Christina Kanaka-Gantenbein, Christina Kogia, Mohamed Badawy Abdel-Naser, George P. Chrousos

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

The human skin is a well-organized organ bearing different types of cells in a well-structured interference to each other including epidermal and follicular keratinocytes, sebocytes, melanocytes, dermal papilla cells and fibroblasts, endothelial cells, sweat gland cells as well as nerves. Several hormones act on different cell types of the skin, while it is also considered an endocrine organ secreting hormones that act at several sites of the organism. GH receptors are found in almost all cell types forming the skin, while IGF-1 receptors’ expression is restricted to the epidermal keratinocytes. Both Growth Hormone (GH) excess, as in the case of Acromegaly in adults, or Gigantism in growing children, and GH deficiency states lead to skin manifestations. In case of GH excess the main dermatological findings are skin thickening, coarsening of facial features, acrochordons, puffy hands and feet, oily skin and hyperhidrosis, while GH deficiency, on the contrary, is characterized by thin, dry skin and disorder of normal sweating. Moreover, special disorders associated with GH excess may have specific characteristics, as is the case of café-au-lait spots in Neurofibromatosis, or big café-au-lait skin hyperpigmented regions with irregular margins, as is the case in McCune-Albright syndrome. Meticulous examination of the skin may therefore contribute to the final diagnosis in cases of GH-induced disorders.
Literatur
1.
Zurück zum Zitat Herrington, J. and C. Carter-Su, Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab, 2001. 12(6): p. 252–7. Herrington, J. and C. Carter-Su, Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab, 2001. 12(6): p. 252–7.
2.
Zurück zum Zitat Brooks, A.J. and M.J. Waters, The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol, 2010. 6(9): p. 515–25. Brooks, A.J. and M.J. Waters, The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol, 2010. 6(9): p. 515–25.
3.
Zurück zum Zitat Gunawardane K et al. Normal Physiology of Growth Hormone in Adults. In: Endotext LJ, Groot D, et al., editors. . South Dartmouth (MA): MDText.com, Inc.; 2000. Gunawardane K et al. Normal Physiology of Growth Hormone in Adults. In: Endotext LJ, Groot D, et al., editors. . South Dartmouth (MA): MDText.com, Inc.; 2000.
4.
Zurück zum Zitat Murray PG, Higham CE, Clayton PE. 60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-GH axis: the past 60 years. J Endocrinol. 2015;226(2):T123–40.CrossRefPubMed Murray PG, Higham CE, Clayton PE. 60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-GH axis: the past 60 years. J Endocrinol. 2015;226(2):T123–40.CrossRefPubMed
5.
Zurück zum Zitat Davidson MB. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev. 1987;8(2):115–31.CrossRefPubMed Davidson MB. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev. 1987;8(2):115–31.CrossRefPubMed
6.
7.
Zurück zum Zitat Zouboulis CC. The human skin as a hormone target and an endocrine gland. Hormones (Athens). 2004;3(1):9–26.CrossRef Zouboulis CC. The human skin as a hormone target and an endocrine gland. Hormones (Athens). 2004;3(1):9–26.CrossRef
8.
Zurück zum Zitat Zouboulis CC. Human skin: an independent peripheral endocrine organ. Horm Res. 2000;54(5–6):230–42.PubMed Zouboulis CC. Human skin: an independent peripheral endocrine organ. Horm Res. 2000;54(5–6):230–42.PubMed
10.
Zurück zum Zitat Tavakkol A et al. Expression of growth hormone receptor, insulin-like growth factor 1 (IGF-1) and IGF-1 receptor mRNA and proteins in human skin. J Invest Dermatol. 1992;99(3):343–9.CrossRefPubMed Tavakkol A et al. Expression of growth hormone receptor, insulin-like growth factor 1 (IGF-1) and IGF-1 receptor mRNA and proteins in human skin. J Invest Dermatol. 1992;99(3):343–9.CrossRefPubMed
11.
Zurück zum Zitat Oakes SR et al. Demonstration and localization of growth hormone receptor in human skin and skin fibroblasts. J Clin Endocrinol Metab. 1992;75(5):1368–73.PubMed Oakes SR et al. Demonstration and localization of growth hormone receptor in human skin and skin fibroblasts. J Clin Endocrinol Metab. 1992;75(5):1368–73.PubMed
12.
Zurück zum Zitat Lobie PE et al. Localization of the growth hormone receptor/binding protein in skin. J Endocrinol. 1990;126(3):467–71.CrossRefPubMed Lobie PE et al. Localization of the growth hormone receptor/binding protein in skin. J Endocrinol. 1990;126(3):467–71.CrossRefPubMed
13.
Zurück zum Zitat Rosenfeld RG, Dollar LA. Characterization of the somatomedin-C/insulin-like growth factor I (SM-C/IGF-I) receptor on cultured human fibroblast monolayers: regulation of receptor concentrations by SM-C/IGF-I and insulin. J Clin Endocrinol Metab. 1982;55(3):434–40.CrossRefPubMed Rosenfeld RG, Dollar LA. Characterization of the somatomedin-C/insulin-like growth factor I (SM-C/IGF-I) receptor on cultured human fibroblast monolayers: regulation of receptor concentrations by SM-C/IGF-I and insulin. J Clin Endocrinol Metab. 1982;55(3):434–40.CrossRefPubMed
14.
Zurück zum Zitat Deplewski D, Rosenfield RL. Growth hormone and insulin-like growth factors have different effects on sebaceous cell growth and differentiation. Endocrinology. 1999;140(9):4089–94.PubMed Deplewski D, Rosenfield RL. Growth hormone and insulin-like growth factors have different effects on sebaceous cell growth and differentiation. Endocrinology. 1999;140(9):4089–94.PubMed
15.
Zurück zum Zitat Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev. 2000;21(4):363–92.CrossRefPubMed Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev. 2000;21(4):363–92.CrossRefPubMed
16.
Zurück zum Zitat Su HY et al. Insulin-like growth factor 1 and hair growth. Dermatol Online J. 1999;5(2):1.PubMed Su HY et al. Insulin-like growth factor 1 and hair growth. Dermatol Online J. 1999;5(2):1.PubMed
17.
Zurück zum Zitat Rudman SM et al. The role of IGF-I in human skin and its appendages: morphogen as well as mitogen? J Invest Dermatol. 1997;109(6):770–7.CrossRefPubMed Rudman SM et al. The role of IGF-I in human skin and its appendages: morphogen as well as mitogen? J Invest Dermatol. 1997;109(6):770–7.CrossRefPubMed
18.
Zurück zum Zitat Edmondson SR et al. Epidermal Homeostasis: The Role of the Growth Hormone and Insulin-Like Growth Factor Systems. Endocr Rev. 2003;24(6):737–64.CrossRefPubMed Edmondson SR et al. Epidermal Homeostasis: The Role of the Growth Hormone and Insulin-Like Growth Factor Systems. Endocr Rev. 2003;24(6):737–64.CrossRefPubMed
19.
Zurück zum Zitat Lemmey AB et al. Differential regulation of tissue insulin-like growth factor-binding protein (IGFBP)-3, IGF-I and IGF type 1 receptor mRNA levels, and serum IGF-I and IGFBP concentrations by growth hormone and IGF-I. J Endocrinol. 1997;154(2):319–28.CrossRefPubMed Lemmey AB et al. Differential regulation of tissue insulin-like growth factor-binding protein (IGFBP)-3, IGF-I and IGF type 1 receptor mRNA levels, and serum IGF-I and IGFBP concentrations by growth hormone and IGF-I. J Endocrinol. 1997;154(2):319–28.CrossRefPubMed
20.
Zurück zum Zitat Lewis, D.A., et al., The IGF-1/IGF-1R signaling axis in the skin: a new role for the dermis in aging-associated skin cancer. Oncogene, 2010. 29(10): p. 1475–85. Lewis, D.A., et al., The IGF-1/IGF-1R signaling axis in the skin: a new role for the dermis in aging-associated skin cancer. Oncogene, 2010. 29(10): p. 1475–85.
22.
23.
Zurück zum Zitat Ben-Shlomo A, Melmed S. Skin manifestations in acromegaly. Clin Dermatol. 2006;24(4):256–9.CrossRefPubMed Ben-Shlomo A, Melmed S. Skin manifestations in acromegaly. Clin Dermatol. 2006;24(4):256–9.CrossRefPubMed
24.
Zurück zum Zitat Centurion SA, Schwartz RA. Cutaneous signs of acromegaly. Int J Dermatol. 2002;41(10):631–4.CrossRefPubMed Centurion SA, Schwartz RA. Cutaneous signs of acromegaly. Int J Dermatol. 2002;41(10):631–4.CrossRefPubMed
25.
Zurück zum Zitat Matsuoka LY et al. Histochemical characterization of the cutaneous involvement of acromegaly. Arch Intern Med. 1982;142(10):1820–3.CrossRefPubMed Matsuoka LY et al. Histochemical characterization of the cutaneous involvement of acromegaly. Arch Intern Med. 1982;142(10):1820–3.CrossRefPubMed
26.
27.
Zurück zum Zitat Resende M et al. Prevalence of dermatologic disorders in 15 patients with acromegaly. An Bras Dermatol. 2012;87(1):166–8.CrossRefPubMed Resende M et al. Prevalence of dermatologic disorders in 15 patients with acromegaly. An Bras Dermatol. 2012;87(1):166–8.CrossRefPubMed
28.
Zurück zum Zitat Baris D et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002;13(5):395–400.CrossRefPubMed Baris D et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002;13(5):395–400.CrossRefPubMed
29.
Zurück zum Zitat Corcuff JB et al. Ocular naevus and melanoma in acromegaly. Clin Endocrinol. 1997;47(1):119–21.CrossRef Corcuff JB et al. Ocular naevus and melanoma in acromegaly. Clin Endocrinol. 1997;47(1):119–21.CrossRef
30.
Zurück zum Zitat Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol. 2002;147(6):1096–101.CrossRefPubMed Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol. 2002;147(6):1096–101.CrossRefPubMed
31.
Zurück zum Zitat Demirkesen C. Skin Manifestations of Endocrine Diseases. Turk Patoloji Derg. 2015;31(Suppl 1):145–54.PubMed Demirkesen C. Skin Manifestations of Endocrine Diseases. Turk Patoloji Derg. 2015;31(Suppl 1):145–54.PubMed
32.
Zurück zum Zitat Lolis MS, Bowe WP, Shalita AR. Acne and Systemic Disease. Med Clin N Am. 2009;93(6):1161–81.CrossRefPubMed Lolis MS, Bowe WP, Shalita AR. Acne and Systemic Disease. Med Clin N Am. 2009;93(6):1161–81.CrossRefPubMed
33.
Zurück zum Zitat Chalmers RJ et al. Acne vulgaris and hidradenitis suppurativa as presenting features of acromegaly. Br Med J (Clin Res Ed). 1983;287(6402):1346–7.CrossRef Chalmers RJ et al. Acne vulgaris and hidradenitis suppurativa as presenting features of acromegaly. Br Med J (Clin Res Ed). 1983;287(6402):1346–7.CrossRef
34.
Zurück zum Zitat Borlu M et al. Acromegaly is associated with decreased skin transepidermal water loss and temperature, and increased skin pH and sebum secretion partially reversible after treatment. Growth Hormon IGF Res. 2012;22(2):82–6.CrossRef Borlu M et al. Acromegaly is associated with decreased skin transepidermal water loss and temperature, and increased skin pH and sebum secretion partially reversible after treatment. Growth Hormon IGF Res. 2012;22(2):82–6.CrossRef
35.
Zurück zum Zitat Kaltsas GA et al. Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab. 1999;84(8):2731–5.CrossRefPubMed Kaltsas GA et al. Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab. 1999;84(8):2731–5.CrossRefPubMed
37.
Zurück zum Zitat Sneppen SB et al. Sweat secretion rates in growth hormone disorders. Clin Endocrinol. 2000;53(5):601–8.CrossRef Sneppen SB et al. Sweat secretion rates in growth hormone disorders. Clin Endocrinol. 2000;53(5):601–8.CrossRef
38.
Zurück zum Zitat Lange M et al. Skin morphological changes in growth hormone deficiency and acromegaly. Eur J Endocrinol. 2001;145(2):147–53.CrossRefPubMed Lange M et al. Skin morphological changes in growth hormone deficiency and acromegaly. Eur J Endocrinol. 2001;145(2):147–53.CrossRefPubMed
39.
Zurück zum Zitat Hasan W et al. The sweating apparatus in growth hormone deficiency, following treatment with r-hGH and in acromegaly. Auton Neurosci. 2001;89(1–2):100–9.CrossRefPubMed Hasan W et al. The sweating apparatus in growth hormone deficiency, following treatment with r-hGH and in acromegaly. Auton Neurosci. 2001;89(1–2):100–9.CrossRefPubMed
40.
Zurück zum Zitat Krsek M et al. The relationship between serum levels of insulin-like growth factor-I and its binding proteins and microvascular function in acromegalic patients. Growth Hormon IGF Res. 2002;12(1):54–9.CrossRef Krsek M et al. The relationship between serum levels of insulin-like growth factor-I and its binding proteins and microvascular function in acromegalic patients. Growth Hormon IGF Res. 2002;12(1):54–9.CrossRef
41.
Zurück zum Zitat Schiavon, F., et al., Morphologic study of microcirculation in acromegaly by capillaroscopy. J Clin Endocrinol Metab, 1999. 84(9): p. 3151–5. Schiavon, F., et al., Morphologic study of microcirculation in acromegaly by capillaroscopy. J Clin Endocrinol Metab, 1999. 84(9): p. 3151–5.
42.
Zurück zum Zitat Daughaday WH. Pituitary gigantism. Endocrinol Metab Clin N Am. 1992;21(3):633–47. Daughaday WH. Pituitary gigantism. Endocrinol Metab Clin N Am. 1992;21(3):633–47.
43.
Zurück zum Zitat Gelber SJ, Heffez DS, Donohoue PA. Pituitary gigantism caused by growth hormone excess from infancy. J Pediatr. 1992;120(6):931–4.CrossRefPubMed Gelber SJ, Heffez DS, Donohoue PA. Pituitary gigantism caused by growth hormone excess from infancy. J Pediatr. 1992;120(6):931–4.CrossRefPubMed
44.
Zurück zum Zitat Zimmerman D et al. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation. J Clin Endocrinol Metab. 1993;76(1):216–22.PubMed Zimmerman D et al. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation. J Clin Endocrinol Metab. 1993;76(1):216–22.PubMed
45.
Zurück zum Zitat Sano T, Asa SL, Kovacs K. Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocr Rev. 1988;9(3):357–73.CrossRefPubMed Sano T, Asa SL, Kovacs K. Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocr Rev. 1988;9(3):357–73.CrossRefPubMed
46.
Zurück zum Zitat Doga M et al. Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects. Ann Oncol. 2001;12(Suppl 2):S89–94.CrossRefPubMed Doga M et al. Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects. Ann Oncol. 2001;12(Suppl 2):S89–94.CrossRefPubMed
47.
Zurück zum Zitat Moran A et al. Gigantism due to pituitary mammosomatotroph hyperplasia. N Engl J Med. 1990;323(5):322–7.CrossRefPubMed Moran A et al. Gigantism due to pituitary mammosomatotroph hyperplasia. N Engl J Med. 1990;323(5):322–7.CrossRefPubMed
48.
Zurück zum Zitat Shimon I, Melmed S. Genetic basis of endocrine disease: pituitary tumor pathogenesis. J Clin Endocrinol Metab. 1997;82(6):1675–81.PubMed Shimon I, Melmed S. Genetic basis of endocrine disease: pituitary tumor pathogenesis. J Clin Endocrinol Metab. 1997;82(6):1675–81.PubMed
49.
Zurück zum Zitat Feldkamp MM, Gutmann DH, Guha A. Neurofibromatosis type 1: piecing the puzzle together. Can J Neurol Sci. 1998;25(3):181–91.CrossRefPubMed Feldkamp MM, Gutmann DH, Guha A. Neurofibromatosis type 1: piecing the puzzle together. Can J Neurol Sci. 1998;25(3):181–91.CrossRefPubMed
50.
Zurück zum Zitat Ledbetter DH et al. Precise localization of NF1 to 17q11.2 by balanced translocation. Am J Hum Genet. 1989;44(1):20–4.PubMedPubMedCentral Ledbetter DH et al. Precise localization of NF1 to 17q11.2 by balanced translocation. Am J Hum Genet. 1989;44(1):20–4.PubMedPubMedCentral
51.
Zurück zum Zitat Evans DG et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152a(2):327–32.CrossRefPubMed Evans DG et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152a(2):327–32.CrossRefPubMed
53.
Zurück zum Zitat Duchowny MS, Katz R, Bejar RL. Hypothalamic mass and gigantism in neurofibromatosis: treatment with bromocriptine. Ann Neurol. 1984;15(3):302–4.CrossRefPubMed Duchowny MS, Katz R, Bejar RL. Hypothalamic mass and gigantism in neurofibromatosis: treatment with bromocriptine. Ann Neurol. 1984;15(3):302–4.CrossRefPubMed
54.
Zurück zum Zitat Eugster E. In: Endotext LJ, Groot D, et al., editors. Gigantism. South Dartmouth (MA).: MDText.com, Inc; 2000. Eugster E. In: Endotext LJ, Groot D, et al., editors. Gigantism. South Dartmouth (MA).: MDText.com, Inc; 2000.
55.
Zurück zum Zitat Nunley, K.S., et al., Predictive value of cafe au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1. Arch Dermatol, 2009. 145(8): p. 883–7. Nunley, K.S., et al., Predictive value of cafe au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1. Arch Dermatol, 2009. 145(8): p. 883–7.
56.
Zurück zum Zitat Korf BR. Diagnostic outcome in children with multiple cafe au lait spots. Pediatrics. 1992;90(6):924–7.PubMed Korf BR. Diagnostic outcome in children with multiple cafe au lait spots. Pediatrics. 1992;90(6):924–7.PubMed
57.
Zurück zum Zitat Landau M, Krafchik BR. The diagnostic value of café-au-lait macules. J Am Acad Dermatol. 1999;40(6):877–90.CrossRefPubMed Landau M, Krafchik BR. The diagnostic value of café-au-lait macules. J Am Acad Dermatol. 1999;40(6):877–90.CrossRefPubMed
58.
Zurück zum Zitat Konrad K, Wolff K, Honigsmann H. The giant melanosome: a model of deranged melanosome-morphogenesis. J Ultrastruct Res. 1974;48(1):102–23.CrossRefPubMed Konrad K, Wolff K, Honigsmann H. The giant melanosome: a model of deranged melanosome-morphogenesis. J Ultrastruct Res. 1974;48(1):102–23.CrossRefPubMed
59.
Zurück zum Zitat Nakagawa H et al. The nature and origin of the melanin macroglobule. J Invest Dermatol. 1984;83(2):134–9.CrossRefPubMed Nakagawa H et al. The nature and origin of the melanin macroglobule. J Invest Dermatol. 1984;83(2):134–9.CrossRefPubMed
60.
Zurück zum Zitat Crowe FW. Axillary Freckling as a Diagnostic Aid in Neurofibromatosis. Ann Intern Med. 1964;61(6):1142–3.CrossRefPubMed Crowe FW. Axillary Freckling as a Diagnostic Aid in Neurofibromatosis. Ann Intern Med. 1964;61(6):1142–3.CrossRefPubMed
61.
Zurück zum Zitat Christoforidis A, Maniadaki I, Stanhope R. McCune-Albright syndrome: growth hormone and prolactin hypersecretion. J Pediatr Endocrinol Metab. 2006;19(Suppl 2):623–5.PubMed Christoforidis A, Maniadaki I, Stanhope R. McCune-Albright syndrome: growth hormone and prolactin hypersecretion. J Pediatr Endocrinol Metab. 2006;19(Suppl 2):623–5.PubMed
62.
Zurück zum Zitat Weinstein LS et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325(24):1688–95.CrossRefPubMed Weinstein LS et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325(24):1688–95.CrossRefPubMed
63.
Zurück zum Zitat Lumbroso S, Paris F, Sultan C. McCune-Albright syndrome: molecular genetics. J Pediatr Endocrinol Metab. 2002;15(Suppl 3):875–82.PubMed Lumbroso S, Paris F, Sultan C. McCune-Albright syndrome: molecular genetics. J Pediatr Endocrinol Metab. 2002;15(Suppl 3):875–82.PubMed
65.
Zurück zum Zitat Thakker RV et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1. J Clin Endocrinol Metab. 2012;97(9):2990–3011.CrossRefPubMed Thakker RV et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1. J Clin Endocrinol Metab. 2012;97(9):2990–3011.CrossRefPubMed
66.
Zurück zum Zitat Stratakis CA et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2000;85(12):4776–80.PubMed Stratakis CA et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 2000;85(12):4776–80.PubMed
67.
Zurück zum Zitat Darling TN et al. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol. 1997;133(7):853–7.CrossRefPubMed Darling TN et al. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol. 1997;133(7):853–7.CrossRefPubMed
68.
Zurück zum Zitat Carney JA, Headington JT, Su WP. Cutaneous myxomas. A major component of the complex of myxomas, spotty pigmentation, and endocrine overactivity. Arch Dermatol. 1986;122(7):790–8.CrossRefPubMed Carney JA, Headington JT, Su WP. Cutaneous myxomas. A major component of the complex of myxomas, spotty pigmentation, and endocrine overactivity. Arch Dermatol. 1986;122(7):790–8.CrossRefPubMed
69.
Zurück zum Zitat Salpea P et al. Deletions of the PRKAR1A locus at 17q24.2-q24.3 in Carney complex: genotype-phenotype correlations and implications for genetic testing. J Clin Endocrinol Metab. 2014;99(1):E183–8.CrossRefPubMed Salpea P et al. Deletions of the PRKAR1A locus at 17q24.2-q24.3 in Carney complex: genotype-phenotype correlations and implications for genetic testing. J Clin Endocrinol Metab. 2014;99(1):E183–8.CrossRefPubMed
70.
Zurück zum Zitat Groussin L et al. A PRKAR1A mutation associated with primary pigmented nodular adrenocortical disease in 12 kindreds. J Clin Endocrinol Metab. 2006;91(5):1943–9.CrossRefPubMed Groussin L et al. A PRKAR1A mutation associated with primary pigmented nodular adrenocortical disease in 12 kindreds. J Clin Endocrinol Metab. 2006;91(5):1943–9.CrossRefPubMed
71.
Zurück zum Zitat Casey M et al. Mutations in the protein kinase A R1alpha regulatory subunit cause familial cardiac myxomas and Carney complex. J Clin Invest. 2000;106(5):R31–8.CrossRefPubMedPubMedCentral Casey M et al. Mutations in the protein kinase A R1alpha regulatory subunit cause familial cardiac myxomas and Carney complex. J Clin Invest. 2000;106(5):R31–8.CrossRefPubMedPubMedCentral
72.
Zurück zum Zitat Stratakis CA et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Investig. 1996;97(3):699–705.CrossRefPubMedPubMedCentral Stratakis CA et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Investig. 1996;97(3):699–705.CrossRefPubMedPubMedCentral
74.
Zurück zum Zitat Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab. 2001;86(9):4041–6.CrossRefPubMed Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab. 2001;86(9):4041–6.CrossRefPubMed
75.
Zurück zum Zitat Pack SD et al. Genetic and Histologic Studies of Somatomammotropic Pituitary Tumors in Patients with the “Complex of Spotty Skin Pigmentation, Myxomas, Endocrine Overactivity and Schwannomas” (Carney Complex). J Clin Endocrinol Metabolism. 2000;85(10):3860–5. Pack SD et al. Genetic and Histologic Studies of Somatomammotropic Pituitary Tumors in Patients with the “Complex of Spotty Skin Pigmentation, Myxomas, Endocrine Overactivity and Schwannomas” (Carney Complex). J Clin Endocrinol Metabolism. 2000;85(10):3860–5.
76.
77.
Zurück zum Zitat Martucci F, Trivellin G, Korbonits M. Familial isolated pituitary adenomas: an emerging clinical entity. J Endocrinol Investig. 2012;35(11):1003–14.CrossRef Martucci F, Trivellin G, Korbonits M. Familial isolated pituitary adenomas: an emerging clinical entity. J Endocrinol Investig. 2012;35(11):1003–14.CrossRef
79.
Zurück zum Zitat Monson JP, Brooke AM, Akker S. Adult Growth Hormone Deficiency. In: Endotext LJ, Groot D, et al., editors. . South Dartmouth (MA).: MDText.com, Inc.:; 2000. Monson JP, Brooke AM, Akker S. Adult Growth Hormone Deficiency. In: Endotext LJ, Groot D, et al., editors. . South Dartmouth (MA).: MDText.com, Inc.:; 2000.
80.
Zurück zum Zitat de Boer H, Blok GJ, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev. 1995;16(1):63–86.CrossRefPubMed de Boer H, Blok GJ, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev. 1995;16(1):63–86.CrossRefPubMed
82.
Zurück zum Zitat Murray PG, Dattani MT, Clayton PE. Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence. Arch Dis Child. 2016;101(1):96–100.CrossRefPubMed Murray PG, Dattani MT, Clayton PE. Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence. Arch Dis Child. 2016;101(1):96–100.CrossRefPubMed
83.
Zurück zum Zitat Rosenfeld RG, Hwa V. New molecular mechanisms of GH resistance. Eur J Endocrinol. 2004;151(Suppl 1):S11–5.CrossRefPubMed Rosenfeld RG, Hwa V. New molecular mechanisms of GH resistance. Eur J Endocrinol. 2004;151(Suppl 1):S11–5.CrossRefPubMed
84.
Zurück zum Zitat Wu W et al. Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet. 1998;18(2):147–9.CrossRefPubMed Wu W et al. Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet. 1998;18(2):147–9.CrossRefPubMed
85.
Zurück zum Zitat Cuneo RC et al. The growth hormone deficiency syndrome in adults. Clin Endocrinol. 1992;37(5):387–97.CrossRef Cuneo RC et al. The growth hormone deficiency syndrome in adults. Clin Endocrinol. 1992;37(5):387–97.CrossRef
86.
Zurück zum Zitat Tanriverdi F et al. Investigation of the skin characteristics in patients with severe GH deficiency and the effects of 6 months of GH replacement therapy: a randomized placebo controlled study. Clin Endocrinol. 2006;65(5):579–85.CrossRef Tanriverdi F et al. Investigation of the skin characteristics in patients with severe GH deficiency and the effects of 6 months of GH replacement therapy: a randomized placebo controlled study. Clin Endocrinol. 2006;65(5):579–85.CrossRef
88.
Zurück zum Zitat Borlu M et al. The effects of severe growth hormone deficiency on the skin of patients with Sheehan’s syndrome. J Eur Acad Dermatol Venereol. 2007;21(2):199–204.CrossRefPubMed Borlu M et al. The effects of severe growth hormone deficiency on the skin of patients with Sheehan’s syndrome. J Eur Acad Dermatol Venereol. 2007;21(2):199–204.CrossRefPubMed
89.
Zurück zum Zitat Blok GJ et al. Growth hormone substitution in adult growth hormone-deficient men augments androgen effects on the skin. Clin Endocrinol. 1997;47(1):29–36.CrossRef Blok GJ et al. Growth hormone substitution in adult growth hormone-deficient men augments androgen effects on the skin. Clin Endocrinol. 1997;47(1):29–36.CrossRef
90.
Zurück zum Zitat Conte F et al. Evaluation of cutaneous modifications in seventy-seven growth hormone-deficient children. Horm Res. 2000;54(2):92–7.PubMed Conte F et al. Evaluation of cutaneous modifications in seventy-seven growth hormone-deficient children. Horm Res. 2000;54(2):92–7.PubMed
91.
Zurück zum Zitat Main K, Nilsson KO, Skakkebaek NE. Influence of sex and growth hormone deficiency on sweating. Scand J Clin Lab Invest. 1991;51(5):475–80.CrossRefPubMed Main K, Nilsson KO, Skakkebaek NE. Influence of sex and growth hormone deficiency on sweating. Scand J Clin Lab Invest. 1991;51(5):475–80.CrossRefPubMed
92.
Zurück zum Zitat Raynal P. Growth hormone and noonan syndrome: update in dysfunctional signaling aspects and in therapy for short stature. Hormonal Studies. 2014;2(1). Raynal P. Growth hormone and noonan syndrome: update in dysfunctional signaling aspects and in therapy for short stature. Hormonal Studies. 2014;2(1).
94.
Zurück zum Zitat Rao E et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet. 1997;16(1):54–63.CrossRefPubMed Rao E et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet. 1997;16(1):54–63.CrossRefPubMed
96.
Zurück zum Zitat Lowenstein EJ, Kim KH, Glick SA. Turner’s syndrome in dermatology. J Am Acad Dermatol. 2004;50(5):767–76.CrossRefPubMed Lowenstein EJ, Kim KH, Glick SA. Turner’s syndrome in dermatology. J Am Acad Dermatol. 2004;50(5):767–76.CrossRefPubMed
97.
100.
Zurück zum Zitat McCandless SE. Clinical report-health supervision for children with Prader-Willi syndrome. Pediatrics. 2011;127(1):195–204.CrossRefPubMed McCandless SE. Clinical report-health supervision for children with Prader-Willi syndrome. Pediatrics. 2011;127(1):195–204.CrossRefPubMed
101.
Zurück zum Zitat Bornhausen-Demarch E et al. Cutaneous manifestations of Prader-Willi syndrome. Cutis. 2012;90(3):129–31.PubMed Bornhausen-Demarch E et al. Cutaneous manifestations of Prader-Willi syndrome. Cutis. 2012;90(3):129–31.PubMed
102.
Zurück zum Zitat Wattendorf DJ, Muenke M. Prader-Willi syndrome. Am Fam Physician. 2005;72(5):827–30.PubMed Wattendorf DJ, Muenke M. Prader-Willi syndrome. Am Fam Physician. 2005;72(5):827–30.PubMed
103.
Zurück zum Zitat Lurie R, Ben-Amitai D, Laron Z. Laron syndrome (primary growth hormone insensitivity): a unique model to explore the effect of insulin-like growth factor 1 deficiency on human hair. Dermatology. 2004;208(4):314–8.CrossRefPubMed Lurie R, Ben-Amitai D, Laron Z. Laron syndrome (primary growth hormone insensitivity): a unique model to explore the effect of insulin-like growth factor 1 deficiency on human hair. Dermatology. 2004;208(4):314–8.CrossRefPubMed
Metadaten
Titel
Skin manifestations of growth hormone-induced diseases
verfasst von
Christina Kanaka-Gantenbein
Christina Kogia
Mohamed Badawy Abdel-Naser
George P. Chrousos
Publikationsdatum
30.08.2016
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 3/2016
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-016-9378-8

Weitere Artikel der Ausgabe 3/2016

Reviews in Endocrine and Metabolic Disorders 3/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.